Profitability Ratios
| Ratio |
Value |
| GP Margin |
30.5% |
| EBIT Margin |
12.6% |
| EBITDA Margin |
22.7% |
| Operating Margin |
12.6% |
| Pretax Margin |
-2.5% |
| Cont. Ops Margin |
-3.5% |
| Net Margin |
-3.6% |
| Bottom Line Margin |
-3.6% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
1.29 |
| Quick Ratio |
1.02 |
| Solvency Ratio |
0.066 |
| Cash Ratio |
0.19 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.04 |
| Forward PEG |
0.04 |
| Price/Book |
3.19 |
| Price/Sales |
2.51 |
| Price/FCF |
19.47 |
| Price/Op Cash Flow |
13.68 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.4296 |
| Debt/Equity |
0.9687 |
| Debt/Capital |
0.4920 |
| Long-Term Debt/Capital |
0.4458 |
| Financial Leverage |
2.25 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
10.92 |
| Operating Cash Flow Ratio |
0.658 |
| Operating Cash Flow/Sales |
18.4% |
| Free Cash Flow/Operating Cash Flow |
70.3% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
5.17 |
| Interest Coverage |
4.7449 |
| Short-Term Operating Cash Flow Coverage |
12.08 |
| Operating Cash Flow Coverage |
0.24 |
| Capital Expenditure Coverage |
3.37 |
| Dividend + Capital Expenditure Coverage |
3.37 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
81.01 |
| EPS |
-2.912 |
| Debt/Share |
64.0090 |
| Cash/Share |
4.31 |
| Book Value/Share |
64.79 |
| Tangible BV/Share |
2.16 |
| Equity/Share |
63.85 |
| Operating Cash Flow/Share |
14.883 |
| Capital Expenditure/Share |
4.422 |
| FCF/Share |
10.461 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.451 |
| Earnings Before Tax/EBIT |
-0.196 |
| Price/Fair Value |
3.19 |
| Debt/Market Cap |
0.2582 |
| Effective Tax Rate |
-42.9% |
| Enterprise Value Multiple |
14.21 |
CRL - Charles River Laboratories International, Inc.